Archives
- 2018-07
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
HOIP s ability to build linear Ub chains arises
2019-09-07
HOIP\'s ability to build linear Ub chains arises from a unique domain that follows directly after the RING2 domain, the linear ubiquitin chain-determining domain (LDD) (Fig. 1). Structures have revealed that the LDD is structurally integrated into RING2, creating a single RING2–LDD unit (Fig. 2D) [4
-
1347 Mulan protein level is regulated with conditions
2019-09-07
Mulan protein level is regulated with conditions that stimulate mitophagy such as treatment of 1347 with CCCP [12]. We found that exogenously expressed GFP-GABARAP and RFP-Mulan could co-precipitate and co-localize in mammalian cells and the degree of co-localization increased when the cells were tr
-
br E mediated E discharge E ligases simultaneously interact
2019-09-07
E3-mediated E2 discharge E3 ligases simultaneously interact with the substrate and the SUMOD charged E2 enzyme to catalyze the discharge of the thioester-bound SUMOD from the E2 to the substrate. E3 interaction with SUMOD via a SIM results in a closed conformation which is highly reactive and lea
-
br Materials and methods br Results br Discussion Natural co
2019-09-07
Materials and methods Results Discussion Natural compounds and their derivatives have been investigated as candidates for the treatment of bone diseases and can also be the sources of nutraceutical agents and therapeutic agents [28]. Using peptides as therapeutic effects on bone-related dis
-
The inhibition of DNMT using AZA dC or DNMT siRNA
2019-09-07
The inhibition of DNMT1 using 5-AZA-dC or DNMT1 siRNA increased TIMP2 protein and mRNA expression, suggesting that TIMP2 expression is down-regulated by DNA methylation in the HDFs. In addition, 5-AZA-dC treatment led to a dose-dependent decrease of DNMT1 protein expression. 5-AZA-dC is a cytosine a
-
The paper is organized as follows http www apexbt com
2019-09-06
The paper is organized as follows. Section 2 gives a brief presentation of the JPEG-LS algorithm and respective hardware implementation. In Section 3 the fault injection model and the simulation-based susceptibility analysis method are reviewed. Section 4 provides a discussion on the susceptibility
-
br Methods br Results br Discussion The findings of
2019-09-06
Methods Results Discussion The findings of this study indicate that an ET system including ET-1 and ET-2 as well as ET receptors are present in the retina and RPE/choroid, and are up-regulated by both hypertension and diabetes. Specifically, individual antagonism of the ETRA or ETRB delive
-
The Ewing sarcoma breakpoint region gene EWSR is
2019-09-06
The Ewing sarcoma breakpoint region 1 gene (EWSR1) is a partner in a large, diverse range of mesenchymal (and some nonmesenchymal) tumors (Tables 1 and 2). As the 5′ partner, EWSR1 is able to fuse with an array of genes. These fusions can generate genetically different but phenotypically identical n
-
Covalent inhibitors are well suited for
2019-09-06
Covalent inhibitors are well suited for targeting the E1 GS-1101 clinical of Ubl modifications. Because the E1 enzymes in Ubl modifications, such as the SUMO E1 and Atg7, have a slow turnover rate (Boggio et al., 2004), prolonged inhibition can be achieved without requiring compounds to be stable i
-
It has been reported about the synthesis of
2019-09-06
It has been reported about the synthesis of benzyl bromide in our previous reports, as shown in , , The synthetic route of compounds – is depicted in , Briefly, the synthesis of pyrimidinedione derivatives was started from commercially available AKT inhibitor VIII . After alkylation of material
-
R 59-022 br Results br Discussion Many assays in the literat
2019-09-06
Results Discussion Many assays in the literature for DBH require the use of catalase to protect the active site from hydrogen peroxide, which is a by-product in the initial step of the reaction. For the non-immobilized enzyme there was a visible increase in the rate with increasing amounts of
-
br Results and discussion br Conclusion Analogues of
2019-09-06
Results and discussion Conclusion Analogues of 1,2,4-triazole and 1,3,4-oxadiazole have been designed, synthesized and characterized. To avoid late stage failure, it is important to study the preliminary pharmacokinetic parameters. The results of pharmacokinetic data suggested that, all molecu
-
Saururus chinensis Lour Baill Saururaceae a perennial
2019-09-06
Saururus chinensis (Lour.) Baill. (Saururaceae), a perennial herb, is widely cultivated in China and southern Korea. It has been traditionally used as folk medicine for the treatment of inflammation, jaundice and gonorrhea [8]. Previous chemical studies of S. chinensis have revealed the presence of
-
Necrostatin 1 In addition to the blockade of airway smooth m
2019-09-06
In addition to the blockade of airway smooth muscle contractions, CysLT1 receptor antagonists also exerted a potent anti-inflammatory effect at this level. The oral administration of MEN91507, Pranlukast, Montelukast, and Zafirlukast also produced a long-lasting inhibition of leukotriene D4-induced
-
For LAU extracted ion chromatograms
2019-09-06
For LAU 399, extracted 5-alpha reductase inhibitors chromatograms of the blank, t0, and t120 samples for the diagnostic product ion m/z 163.0216 are provided in Fig. S11, and extracted ion chromatograms of the t120 sample for m/z 163.0216 (diagnostic product ion), and m/z 308.1677 and 306.1522 (met
15302 records 989/1021 page Previous Next First page 上5页 986987988989990 下5页 Last page